James Frates, Chief Financial Officer of Alkermes, Inc., will present an overview of the company at 11:30am ET on Wednesday, November 28, 2001, from The Hotel Inter-Continental, Paris, France.
Alkermes is a leader in the development of products based on sophisticated drug delivery technologies. Its first product, Nutropin Depot(R), is a long-acting form of Genentech's recombinant human growth hormone using Alkermes' ProLease(R) technology. The company has several areas of focus, including (i) controlled, sustained release of injectable drugs lasting several days to several weeks, utilizing its ProLease and Medisorb(R) technologies and (ii) the development of pharmaceutical products based on proprietary pulmonary drug delivery technologies utilizing its AIR(TM) technology. In addition to its Cambridge, Massachusetts headquarters, research and manufacturing facilities, Alkermes operates research and manufacturing facilities in Ohio and a medical affairs office in Cambridge, England.
CONTACT: Alkermes, Inc.
James M. Frates
Chief Financial Officer
(617) 494-0171
URL: http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2001 Business Wire. All rights reserved.